paracetamol + codeine phosphate

Brimisol is a fixed-dose combination analgesic containing **paracetamol** (acetaminophen) and **codeine phosphate**. Developed and marketed by **Bristol Laboratories**, it is primarily indicated for the short-term management of moderate acute pain that is not adequately relieved by single-ingredient analgesics such as paracetamol or ibuprofen alone. Paracetamol provides analgesic and antipyretic effects, likely through the inhibition of cyclooxygenase (COX) enzymes in the central nervous system, thereby reducing prostaglandin synthesis. Codeine phosphate is an opioid analgesic that acts as a prodrug for morphine; it functions as an agonist at mu-opioid receptors to alter the perception of and emotional response to pain. Brimisol is available in various strengths, including 500mg/8mg and 500mg/30mg formulations, and is approved for use in the United Kingdom.

Brand names

Brimisol

Other names

co-codamolacetaminophen + codeine phosphate